Prosecution Insights
Last updated: October 01, 2026
Application No. 18/906,261

Compositions Containing a UV-Absorbing System Including Physical UV-Attenuating Material, Trihydroxystearin and Fatty Acid Oil For Inhibiting Trihydroxystearin Crystallization

Non-Final OA §102§103§112§DP
Filed
Oct 04, 2024
Examiner
AL-AWADI, DANAH J
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
1y 2m
Est. Remaining
68%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
443 granted / 817 resolved
-5.8% vs TC avg
Moderate +13% lift
Without
With
+13.4%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
32 currently pending
Career history
846
Total Applications
across all art units

Statute-Specific Performance

§101
3.1%
-36.9% vs TC avg
§103
47.2%
+7.2% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
21.2%
-18.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 817 resolved cases

Office Action

§102 §103 §112 §DP
DETAILED ACTION 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-25 are pending. INFORMATION DISCLOSURE STATEMENT 2. No Information Disclosure Statement has been submitted for review. Claim Rejections- 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-15 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the term preferably twice in line two and renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 3 recites the term preferably which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 11 recites the term preferably which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 12 recites the term preferably which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 13 recites the term preferably in lines 2 and 3 which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 14 recite the term preferably which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. Claim 15 recite the term preferably which renders the claim indefinite because it is not clear if the limitations following the term preferably are part of the claim or not. 4. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 9-10 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 9 recites the composition contains at least one physical UV absorbing system and depends from claim 1 however, claim 1 already recites this limitation. Claim 10 recites the physical ultraviolet attenuating material which is already recited in claim 1 and is therefore not further limiting. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections- 35 USC § 102 5. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-5, 7-8 and 12-14 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gans Russ et al. (US 2007/0092462). Gans Russ et al. (US 2007/0092462) (hereinafter Gans Russ et al.) disclose cosmetic compositions that contain surface coated titanium dioxide at 8 % (titanium dioxide, triethoxycarpylsilate physical UV attenuating material), zinc oxide and isopropyl isostearate (fatty acid oil). The composition is devoid of organic UV filters. The compositions are in emulsion form such as creams (para 0255). With regards t claim 5 this is future intended use that occurs after application to keratinous material. Furthermore, it is property of the composition and since the same structural features are disclosed, the property would be necessarily present. Claims 12-14 read on having zinc oxide and/or titanium dioxide. Claim Rejections- 35 USC § 103 6. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1, 6 and 15 and rejected under 35 U.S.C. 103 as being unpatentable over Gans Russ et al (US 2007/0092462). Gans Russ et al. has been discussed supra in the 102. With regards to the particle size of claims 6 and 15, Gans Russ et al. disclose the titanium dioxide or zinc oxide has particle sizes ranging from 0.001-150 microns which is a range that overlaps with the instant claims. In the case where the claimed ranges "overlap or lie inside ranges disclosed by the prior art" a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976); In re Woodruff, 919 F.2d 1575, 16 USPQ2d 1934 (Fed. Cir. 1990) (The prior art taught carbon monoxide concentrations of "about 1-5%" while the claim was limited to "more than 5%." The court held that "about 1-5%" allowed for concentrations slightly above 5% thus the ranges overlapped.); In re Geisler, 116 F.3d 1465, 1469-71, 43 USPQ2d 1362, 1365-66 (Fed. Cir. 1997) (Claim reciting thickness of a protective layer as falling within a range of "50 to 100 Angstroms" considered prima facie obvious in view of prior art reference teaching that "for suitable protection, the thickness of the protective layer should be not less than about 10 nm [i.e., 100 Angstroms]." The court stated that "by stating that ‘suitable protection’ is provided if the protective layer is ‘about’ 100 Angstroms thick, [the prior art reference] directly teaches the use of a thickness within [applicant’s] claimed range."). See also In re Bergen, 120 F.2d 329, 332, 49 USPQ 749, 751-52 (CCPA 1941) (The court found that the overlapping endpoint of the prior art and claimed range was sufficient to support an obviousness rejection, particularly when there was no showing of criticality of the claimed range). 7. Claims 1, 12-14 are rejected under 35 U.S.C. 103 as being unpatentable over Gans Russ et al. (US 2007/0092462) as applied to claims 1,6 and 15 above, and further in view of (JP 3769328). Gans Russ et al. has been discussed supra and does not disclosed passivated inorganic pigment (Titanium dioxide or zinc oxide). JP 3769328 disclose that passivated inorganic pigments no longer show a color change or little color change (paras 0011 and 0019). It would have been prima facie obvious to one of ordinary skill in the art before the effective filing date of the instant invention to have the inorganic pigment titanium dioxide or zinc oxide be passivated. One would have been motivated to do so because it would obtain a composition that no longer produces a significant coloring effect over time. DOUBLE PATENTING 8. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-15 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-16 of copending Application No. 18906316. Although the claims at issue are not identical, they are not patentably distinct from each other because both are drawn to physical UV attenuating material that is inclusive of metal oxides and fatty acid oils. The differences being claim 1 of the copending application recites fatty ester of polyol and devoid of organic UV filters however, the scope of the instantly claimed invention of fatty acid oils is inclusive of fatty acid ester of polyols. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. CORRESPONDENCE 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danah Al-awadi whose telephone number is (571) 270-7668. The examiner can normally be reached on 9:00 am - 6:00 pm; M-F (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Danah Al-Awadi/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Oct 04, 2024
Application Filed
Jul 01, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12734124
EYELASH COATING COMPOSITIONS FOR FALSE EYELASHES
2y 9m to grant Granted Sep 15, 2026
Patent 12728134
LIQUISOLID PHARMACEUTICAL FORMULATION AND PROCESS FOR MANUFACTURING
3y 10m to grant Granted Sep 08, 2026
Patent 12721804
EMULSIFIED LIP GEL
4y 2m to grant Granted Sep 01, 2026
Patent 12721831
TETRAHYDROCURCUMINOID-METAL COMPLEXES, MANUFACTURING METHODS THEREOF, AND USES THEREOF
2y 4m to grant Granted Sep 01, 2026
Patent 12714725
STABILIZATION OF SELENITE IN A NUTRITIONAL SOLUTION BY DISSOLVED OXYGEN
4y 2m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
68%
With Interview (+13.4%)
3y 2m (~1y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 817 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month